Description

Thio-Lipon-Novofarm (a-lipoic acid) solution for infusions 30 mg/ml. 20 ml. vial №5

Ingredients

Active ingredient: a-lipoic acid.
Other ingredients: sodium hydroxide, water for injections.

Dosage

Recommended dosage: As directed by a healthcare professional.
The usual adult dosage is 600 mg daily via intravenous infusion.

Indications

Thio-Lipon-Novofarm (a-lipoic acid) solution for infusions is indicated for the treatment of diabetic neuropathy and other conditions where an antioxidant effect is desired.

Contraindications

Do not use Thio-Lipon-Novofarm (a-lipoic acid) solution for infusions if:
– You are allergic to a-lipoic acid or any other ingredients in the product.
– You have a known hypersensitivity to thioctic acid.

Directions

– Thio-Lipon-Novofarm (a-lipoic acid) solution for infusions is for intravenous use only.
– It should be administered by healthcare professionals in a clinical setting.

Scientific Evidence

A-lipoic acid has been extensively studied for its antioxidant properties and its potential benefits in various conditions, including diabetic neuropathy. Research suggests that a-lipoic acid may help improve nerve function and reduce symptoms of neuropathy by reducing oxidative stress and inflammation in the body.

Additional Information

– Thio-Lipon-Novofarm (a-lipoic acid) solution for infusions is well-tolerated in most patients.
– It is important to follow the recommended dosage and administration guidelines to ensure safety and efficacy.

Pharmacological Effects: A-lipoic acid acts as a powerful antioxidant, scavenging free radicals and reducing oxidative stress in the body. It also plays a role in energy production within cells, potentially aiding in the treatment of conditions like diabetic neuropathy.

Clinical Trials: Several clinical trials have demonstrated the efficacy of a-lipoic acid in improving symptoms of diabetic neuropathy and reducing neuropathic pain. For example, a study published in the “Journal of Diabetes Care” showed that a-lipoic acid significantly improved neuropathic symptoms compared to a placebo.